N. Saijo

Masahiro Tsuboi, Iver Petersen, Hisao Asamura, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.

Young Hak Kim, N. Saijo, Y. Nishiwaki, 2009, Lung cancer.

Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities

N. Saijo, Y. Nishiwaki, T. Tamura, 1995, Japanese journal of cancer research : Gann.

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, A. Nicholson, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A case report of synchronous small cell lung cancer and gastric cancer successfully treated with carboplatin.

H. Tajiri, K. Eguchi, N. Saijo, 1986, Japanese journal of cancer research : Gann.

In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin

J. Jett, N. Saijo, W. Hong, 2004, Cancer Chemotherapy and Pharmacology.

Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2010, Cancer Chemotherapy and Pharmacology.

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion

K. Eguchi, N. Saijo, Y. Ohe, 1994, Japanese journal of cancer research : Gann.

Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study.

M. Tsuboi, K. Mori, N. Saijo, 2006, Japanese journal of clinical oncology.

Cellular balance of glutathione levels through the expression of gamma-glutamylcysteine synthetase and glutathione thiol transferase genes in human hepatic cells resistant to a glutathione poison.

N. Saijo, K. Kohno, T. Uchiumi, 1999, Biochimica et biophysica acta.

Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway

Kazuko Sakai, N. Saijo, H. Yokote, 2007, Cancer science.

Cancer chemotherapy in the elderly.

N. Saijo, H. Fukuda, H. Kunitoh, 1998, Japanese journal of clinical oncology.

Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review.

J. Minna, N. Saijo, K. Nishio, 2007, Japanese journal of clinical oncology.

Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma.

N. Saijo, Y. Shimosato, N. Yanaihara, 1989, Cancer research.

Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant

Teruhiko Yoshida, N. Saijo, K. Muro, 2012, Immunogenetics.

Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib

N. Saijo, K. Nishio, T. Shimoyama, 2005, International journal of cancer.

Genetic immunotherapy by intrapleural, intraperitoneal and subcutaneous injection of IL‐2 gene‐modified Lewis lung carcinoma cells

T. Ohira, N. Saijo, Y. Ohe, 1997, International journal of cancer.

Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action.

N. Saijo, K. Nishio, M. Fukuda, 1994, Biochemical and biophysical research communications.

Clinical Trials of Irinotecan Hydrochloride (CPT, Campto Injection, Topotecin Injection) in Japan a

N. Saijo, 1996, Annals of the New York Academy of Sciences.

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.

H. Ohmatsu, R. Kakinuma, K. Eguchi, 1997, British Journal of Cancer.

Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.

N. Saijo, Y. Nishiwaki, Y. Kawakami, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.

K. Mori, N. Saijo, H. Kunikane, 2009, Japanese journal of clinical oncology.

Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition

N. Saijo, Kaoru Tanaka, K. Nishio, 2010, Cancer science.

In vitro thermo- and thermochemo-sensitivity of retinoblastoma cells from surgical specimens

N. Saijo, A. Kaneko, M. Inomata, 2002, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cells

N. Saijo, K. Nishio, Y. Koh, 2004, International journal of cancer.

Long‐term follow‐up of patients with unresectable locally advanced non‐small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)

N. Saijo, Y. Nishiwaki, Y. Ohe, 2003, Cancer science.

Identification of a predictive biomarker for hematologic toxicities of gemcitabine.

H. Ueno, Tesshi Yamada, S. Hirohashi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Geographic variation in the second-line treatment of non-small cell lung cancer.

N. Saijo, M. Edelman, T. Tamura, 2006, Seminars in oncology.

Long-term human hematopoiesis in SCID-hu mice bearing transplanted fragments of adult bone and bone marrow cells.

N. Saijo, Y. Heike, M. Takahashi, 1995, Blood.

Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2006, Clinical pharmacology and therapeutics.

Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2007, Drug metabolism and pharmacokinetics.

Genetic polymorphisms and haplotypes of por, encoding cytochrome p450 oxidoreductase, in a Japanese population.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2011, Drug metabolism and pharmacokinetics.

Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer.

N. Saijo, A. Ohtsu, Y. Sasaki, 1994, Journal of the National Cancer Institute.

CPT‐11: Population Pharmacokinetic Model and Estimation of Pharmacokinetics Using the Bayesian Method in Patients with Lung Cancer

K. Eguchi, N. Saijo, Y. Ohe, 1994, Japanese journal of cancer research : Gann.

A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38

K. Eguchi, N. Saijo, Y. Ohe, 1995, Japanese journal of cancer research : Gann.

Efficient Sampling Strategies for Forecasting Pharmacokinetic Parameters of Irinotecan (CPT‐11): Implication for Area Under the Concentration‐Time Curve Monitoring

H. Ohmatsu, K. Eguchi, N. Saijo, 1995, Therapeutic drug monitoring.

Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1).

H. Ueno, Teruhiko Yoshida, N. Saijo, 2006, Drug metabolism and pharmacokinetics.

Decreased Expression of α2,8 Sialyltransferase and Increased Expression of β1,4 N-Acetylgalactosaminyltransferase in Gastrointestinal Cancers

N. Saijo, K. Nishio, H. Fukumoto, 2002 .

Reversal of adriamycin resistance with chimeric anti‐ganglioside GM2 antibody

N. Saijo, K. Nishio, H. Fukumoto, 1996, International journal of cancer.

In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay.

N. Miyazawa, N. Saijo, Y. Sasaki, 1986, Anticancer research.

Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.

H. Ohmatsu, R. Kakinuma, N. Saijo, 2007, Lung cancer.

A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer.

N. Saijo, N. Yamamoto, K. Hotta, 2001, Japanese journal of clinical oncology.

Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells.

J. Usuda, N. Saijo, K. Nishio, 2001, Lung cancer.

Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer.

N. Saijo, Y. Nishiwaki, K. Kubota, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation

S. Kudoh, N. Saijo, Y. Ohashi, 2011, British Journal of Cancer.

Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.

N. Saijo, Y. Ichinose, Y. Nishiwaki, 2010, Japanese journal of clinical oncology.

Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.

M. Tsuboi, N. Saijo, Y. Ohashi, 2009, Japanese journal of clinical oncology.

FUNCTIONAL CHARACTERIZATION OF FIVE NOVEL CYP 2 C 8 VARIANTS , G 171 S , R 186 X , R 186 G , K 247 R , AND K 383 N , FOUND IN A JAPANESE POPULATION

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2005 .

FUNCTIONAL CHARACTERIZATION OF FIVE NOVEL CYP2C8 VARIANTS, G171S, R186X, R186G, K247R, AND K383N, FOUND IN A JAPANESE POPULATION

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2005, Drug Metabolism and Disposition.

Cytoskeletons and antimitotic agents developed in Japan.

N. Saijo, K. Nishio, 1999, Anti-cancer drug design.

Mechanisms of Action of Cancer Chemotherapeutic Agents: Topoisomerase Inhibitors

N. Saijo, K. Nishio, Y. Koh, 2005 .

FUNCTIONAL ANALYSIS OF SIX HUMAN ARYL HYDROCARBON RECEPTOR VARIANTS IN A JAPANESE POPULATION

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2005, Drug Metabolism and Disposition.

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.

N. Saijo, Y. Ohe, K. Nishio, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Basic Design Considerations for Clinical Trials in Oncology

S. Piantadosi, N. Saijo, T. Tamura, 1992, Japanese journal of cancer research : Gann.

Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials.

Edward S. Kim, N. Saijo, A. Armour, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.

N. Saijo, A. Basu, K. Weixel, 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Establishment of a human leukemia subline resistant to the growth‐inhibitory effect of 12‐o‐tetradecanoylphorbol 13‐acetate (TPA) and showing non‐P‐glycoprotein‐mediated multi‐drug resistance

N. Saijo, Y. Fujiwara, K. Nishio, 1991, International journal of cancer.

A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.

N. Saijo, M. Fukuoka, S. Kudoh, 2011, Japanese journal of clinical oncology.

Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?

H. Choy, H. Wakelee, N. Saijo, 2008, Clinical lung cancer.

Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902.

N. Saijo, M. Fukuoka, K. Kubota, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments]

N. Saijo, K. Shimokata, T. Tamura, 1998, British Journal of Cancer.

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

K. Mori, N. Saijo, Y. Nishiwaki, 2002, The New England journal of medicine.

Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line

N. Saijo, Y. Fujiwara, F. Oshita, 2005, Journal of Cancer Research and Clinical Oncology.

Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.

N. Saijo, H. Yokote, K. Nishio, 1996, Anticancer research.

Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay

K. Eguchi, N. Saijo, Y. Ohe, 2004, Cancer Chemotherapy and Pharmacology.

Topoisomerase i targeting agents in small-cell lung cancer

N. Saijo, Y. Ohe, Y. Ohe, 2001, Current oncology reports.

Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.

N. Saijo, Y. Ichinose, M. Fukuoka, 2008, Japanese journal of clinical oncology.

Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients.

N. Saijo, Y. Ohe, T. Tamura, 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.

R. Tsuchiya, H. Asamura, N. Saijo, 2005, Lung cancer.

Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials.

N. Saijo, Y. Ohe, T. Tamura, 2004, Cancer treatment reviews.

Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs.

N. Saijo, N. Yamamoto, T. Tamura, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on dose-limiting toxicity.

N. Saijo, N. Yamamoto, T. Tamura, 2000, Japanese journal of clinical oncology.

Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

S. Mandrekar, N. Saijo, D. Gandara, 2015 .

Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.

N. Saijo, T. Tamura, H. Kunitoh, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efforts in Lung Cancer : Focus on Early-Stage Non – Small-Cell Lung Cancer comprehensive review

H. Choy, H. Wakelee, N. Saijo, 2011 .

Disparities in gastric cancer chemotherapy between the East and West.

N. Saijo, S. Yoshida, A. Ohtsu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification

Fergus Gleeson, Heber MacMahon, Jin Mo Goo, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.

H. Ueno, Teruhiko Yoshida, N. Saijo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.

M. Tsuboi, K. Eguchi, N. Saijo, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

The final results of a randomized phase III trial comparing irinotecan (CPT-11) and cisplatin (CDDP) with vindesine (VDS) and CDDP in advanced non-small cell lung cancer (NSCLC)

N. Saijo, Y. Nishiwaki, Y. Ohashi, 2000 .

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

N. Saijo, Haiyi Jiang, H. Murakami, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents.

N. Saijo, I. Sekine, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Trials for Lung Cancer in Progress in Japan

N. Saijo, Y. Ohe, T. Tamura, 2006 .

Basic Treatment Strategies for Lung Cancer

N. Saijo, A. Inoue, 2003 .

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2003 .

Irinotecan Combined with Radiation Therapy for Patients with Stage III Non-Small-Cell Lung Cancer: Current Trials.

N. Saijo, 2002, Clinical lung cancer.

7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials

K. Eguchi, N. Saijo, Y. Ohe, 2004, Cancer Chemotherapy and Pharmacology.

New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.

N. Saijo, 1998, Chest.

Phase I Study of a Weekly Infusion of Irinotecan Hydrochloride (CPT‐11) and a 14-day Continuous Infusion of Etoposide in Patients with Lung Cancer: Japan Clinical Oncology Group 9408

N. Saijo, Y. Ohe, Y. Matsuno, 2000 .

Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.

N. Saijo, Y. Nishiwaki, Y. Ohe, 2000, Japanese journal of clinical oncology.

Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.

N. Saijo, Y. Nishiwaki, M. Fukuoka, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.

K. Suemasu, N. Saijo, Y. Nishiwaki, 1991, Journal of the National Cancer Institute.

Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status.

K. Eguchi, N. Saijo, Y. Ohe, 1996, Japanese journal of clinical oncology.

Roentgenographically occult small-cell lung cancer: case report and review of the literature.

N. Saijo, Y. Sasaki, I. Sekine, 1996, Mayo Clinic proceedings.

Severe Interstitial Lung Disease Associated with Amrubicin Treatment

H. Ohmatsu, N. Saijo, Y. Nishiwaki, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124

N. Saijo, D. Gandara, H. Lenz, 2007 .

Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer.

N. Saijo, K. Kubota, T. Shinkai, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer.

N. Saijo, Y. Nishiwaki, Y. Ohe, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors and prognostic staging system for small cell lung cancer.

N. Saijo, Y. Nishiwaki, M. Fukuoka, 1997, Japanese journal of clinical oncology.

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

N. Saijo, Y. Nishiwaki, M. Fukuoka, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Highlights for ESMO 40: celebration review for lifetime achievement awards

N. Saijo, 2016, ESMO Open.

Is radiotherapy optimally combined with chemotherapy in elderly patients with limited-stage small-cell lung cancer?

N. Saijo, 2005, Nature Clinical Practice Oncology.

Progress in treatment of small-cell lung cancer: role of CPT-11

N. Saijo, 2003 .

Concurrent versus sequential radiotherapy for small cell lung cancer.

N. Saijo, K. Goto, M. Takada, 2001, Seminars in oncology.

Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.

N. Saijo, Y. Nishiwaki, M. Fukuoka, 1994, Japanese journal of clinical oncology.

A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.

M. Shibuya, H. Ohmatsu, N. Saijo, 2014, Clinical lung cancer.

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.

K. Mori, N. Saijo, Y. Ichinose, 2012, Lung cancer.

Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402).

N. Saijo, Y. Ichinose, Y. Ohe, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.

N. Saijo, D. Gandara, K. Chansky, 2010, Cancer.

Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.

M. Tsuboi, K. Mori, K. Eguchi, 2010, Anticancer research.

Re-challenge chemotherapy for relapsed non-small-cell lung cancer.

Young Hak Kim, H. Ohmatsu, N. Saijo, 2010, Lung cancer.

Phase II study of (glycolate-O,O′) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer

K. Eguchi, N. Saijo, Y. Ohe, 2008, Cancer Chemotherapy and Pharmacology.

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

N. Saijo, S. Kudoh, H. Kunikane, 2007, British Journal of Cancer.

Phase I Study of Combination Therapy with Interleukin 2 and ^-Interferon in Patients with Advanced Malignancy1

N. Saijo, Y. Fujiwara, Masanori, 2006 .

Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.

N. Saijo, Y. Ohe, T. Tamura, 2002, Japanese journal of clinical oncology.

Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level

K. Eguchi, N. Saijo, W. Hong, 1988, Japanese journal of cancer research : Gann.

Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan

L. Seymour, N. Saijo, M. Forster, 2010, Clinical Cancer Research.

Phase I study of weekly docetaxel (DTX) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) for stage III non-small cell lung cancer (NSCLC)

R. Kakinuma, N. Saijo, Y. Ohe, 2000 .

Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells

J. Usuda, N. Saijo, K. Nishio, 2002, Cancer Chemotherapy and Pharmacology.

Lung cancer working group report.

T. Mitsudomi, Keunchil Park, T. Mok, 2010, Japanese journal of clinical oncology.

Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials

J. Crowley, N. Saijo, Y. Nishiwaki, 2004 .

Phase II study of UFT in patients with advanced non-small cell lung cancer.

K. Eguchi, N. Saijo, N. Keicho, 1986, Japanese journal of clinical oncology.

Evidence‐based clinical practice guidelines for bladder cancer (Summary – JUA 2009 Edition)

H. Nishiyama, N. Saijo, Y. Mizutani, 2010, International journal of urology : official journal of the Japanese Urological Association.

A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer

N. Saijo, Y. Ohe, N. Yamamoto, 2009, Cancer Chemotherapy and Pharmacology.

Histologic types of lung carcinoma and related family history of anatomic sites and histologic types of cancers

T. Naruke, N. Saijo, K. Kubota, 1999, Cancer.

Translational studies for target-based drugs

N. Saijo, Y. Fujiwara, K. Nishio, 2005, Cancer Chemotherapy and Pharmacology.

What are the reasons for negative phase III trials of molecular‐target‐based drugs?

N. Saijo, 2004, Cancer science.

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.

T. Mok, Yi-long Wu, S. Thongprasert, 2017, Lung cancer.

Biological, pathological and clinical features of small cell lung cancer.

S. Hirohashi, K. Suemasu, N. Saijo, 1986, Cancer letters.

Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS).

T. Mok, Yi-long Wu, S. Thongprasert, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of survival in nonresected well differentiated and poorly differentiated adenocarcinoma of the lung

S. Ishikawa, K. Eguchi, K. Tominaga, 2004, Journal of Cancer Research and Clinical Oncology.

Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study

N. Saijo, Y. Nishiwaki, M. Fukuoka, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.

Young Hak Kim, H. Ohmatsu, N. Saijo, 2006, Japanese journal of clinical oncology.

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

Kenji Eguchi, Masahiro Tsuboi, Masahiro Fukuoka, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Yan Sun, Li Zhang, John V Heymach, 2010, The Lancet. Oncology.

Hypersensitivity of NIH3T3 cells transformed by H‐RAS gene to DNA‐topoisomerase‐I inhibitors

H. Kato, T. Ohira, N. Saijo, 1996, International journal of cancer.

Drug resistance in lung cancer.

N. Saijo, K. Nishio, H. Fukumoto, 1999, Current opinion in oncology.

Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect

Teruhiko Yoshida, N. Saijo, H. Sakamoto, 2014, PloS one.

A Computational Model for Quantitative Analysis of Cell Cycle Arrest and Its Contribution to Overall Growth Inhibition by Anticancer Agents

J. Usuda, N. Saijo, K. Nishio, 2000, Japanese journal of cancer research : Gann.

Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation

H. Kato, N. Saijo, H. Arioka, 2005, Journal of Cancer Research and Clinical Oncology.

CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver

N. Saijo, K. Nishio, T. Tamura, 2001, Japanese journal of cancer research : Gann.

Re: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

N. Saijo, M. Ando, M. Narabayashi, 2003, Journal of the National Cancer Institute.

Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin

N. Saijo, K. Nishio, H. Fukumoto, 2002, Japanese journal of cancer research : Gann.

Serum levels of cytokines in patients with untreated primary lung cancer.

K. Eguchi, N. Saijo, Y. Ohe, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of synergism by a novel three‐dimensional model for the combined action of cisplatin and etoposide on the growth of a human small‐cell lung‐cancer cell line, SBC‐3

N. Saijo, K. Nishio, K. Fukuoka, 1997, International journal of cancer.

A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies

N. Saijo, F. Rojo, A. Ohtsu, 2005 .

Phase II Study of 3-Hour Infusion of Paclitaxel in Previously Untreated Non-Small Cell Lung Cancer 1

N. Saijo, Y. Nishiwaki, S. Yoneda, 2005 .

Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.

N. Saijo, Y. Nishiwaki, T. Tamura, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

and Pharmacodynamics of Paclitaxel: A 3-Hour Infusionversus a 24-Hour Infusion'

N. Saijo, Y. Nishiwaki, T. Tamura, 1995 .

Disparities in cancer care: a worldwide perspective and roadmap for change.

Charles R. Thomas, O. Olopade, N. Saijo, 2006, Journal of Clinical Oncology.

Can dose-dense chemotherapy improve outcome in patients with better-prognosis small-cell lung cancer?

N. Saijo, K. Kiura, 2005, Nature Clinical Practice Oncology.

Abstract 1639: The novel c-MET inhibitor, ARQ 197, shows additive growrh-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via ubiquitin/proteasome pathway

N. Saijo, S. Akinaga, M. Adachi, 2010 .

Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin

H. Ueno, Teruhiko Yoshida, N. Saijo, 2005, Clinical Cancer Research.

Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2008, Drug metabolism and pharmacokinetics.

A Topoisomerase II Inhibitor, NK109, Induces DNA Single‐ and Double‐strand Breaks and Apoptosis

N. Saijo, K. Nishio, H. Arioka, 1996, Japanese journal of cancer research : Gann.

Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2007, Journal of Human Genetics.

Gastrin-releasing Peptide as a Specific Tumor Marker in Patients with Small Cell Lung Carcinoma 1

N. Saijo, Y. Shimosato, N. Yanaihara, 2006 .

Postoperative adjuvant treatments for non-small cell lung cancers: a consensus report

D. Ettinger, J. Jett, P. Houtte, 1991 .

Determinants of Drug Response in a Cisplatin‐resistant Human Lung Cancer Cell Line

N. Saijo, Y. Fujiwara, K. Tew, 1990, Japanese journal of cancer research : Gann.

Establishment of a human small‐cell lung‐cancer subline resistant to okadaic acid

S. Kudoh, N. Saijo, S. Kudoh, 1994, International journal of cancer.

mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.

N. Saijo, Kaoru Tanaka, K. Nishio, 2009, Cancer research.

Genetic variations of the AHR gene encoding aryl hydrocarbon receptor in a Japanese population.

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2004, Drug metabolism and pharmacokinetics.

Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients.

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2011, Drug metabolism and pharmacokinetics.

Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines.

J. Yokota, N. Saijo, K. Tew, 1990, The Journal of biological chemistry.

Characterization of a Taxol‐resistant Human Small‐cell Lung Cancer Cell Line

T. Ohira, N. Saijo, K. Nishio, 1994, Japanese journal of cancer research : Gann.

The different effects of recombinant human tumor necrosis factor on rat fibrosarcoma sublines

J. Jett, N. Saijo, W. Hong, 2004, Cancer Immunology and Immunotherapy.

In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay

N. Saijo, Y. Fujiwara, W. Hong, 1987, Investigational New Drugs.

Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines.

N. Saijo, K. Nishio, T. Tamura, 2002, Lung cancer.

Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene

N. Saijo, H. Yokote, K. Nishio, 1997, Japanese journal of cancer research : Gann.

Subcutaneous Administration of Recombinant Human Granulocyte Colony‐stimulating Factor (KRN8601) in Intensive Chemotherapy for Patients with Advanced Lung Cancer

K. Eguchi, K. Suemasu, N. Saijo, 1990, Japanese journal of cancer research : Gann.

Small cell lung cancer.

A. Gregor, P. Rocmans, P. Postmus, 1997, Lung cancer.

Genistein, a Tyrosine Kinase Inhibitor, Decreased the Affinity of p56lck to β-Chain of Interleukin-2 Receptor in Human Natural Killer (NK)-Rich Cells and Decreased NK-Mediated Cytotoxicity

N. Saijo, K. Nishio, Y. Heike, 1994, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Cytogenetic effects of etoposide (VP-16) on human lymphocytes; with special reference to the relation between sister chromatid exchange and chromatid breakage.

K. Tominaga, N. Saijo, T. Nakajima, 1986, Japanese journal of cancer research : Gann.

Functional analysis of four naturally occurring variants of human constitutive androstane receptor.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2005, Molecular genetics and metabolism.

An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells.

N. Saijo, T. Kondo, M. Mutoh, 1998, Experimental cell research.

Differential gene expression profiles and identification of the genes relevant to clinicopathologic factors in colorectal cancer selected by cDNA array method in combination with principal component analysis.

N. Saijo, K. Nishio, H. Yamaue, 2003, International journal of oncology.

Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience.

N. Saijo, M. Fukuoka, N. Yamamoto, 1999, International journal of oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.

N. Saijo, M. Fukuoka, Y. Sasaki, 2000, Japanese journal of clinical oncology.

In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice

T. Ohira, N. Saijo, K. Nishio, 2004, Cancer Chemotherapy and Pharmacology.

Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.

N. Saijo, K. Nishio, H. Kurokawa, 1997, British Journal of Cancer.

Ouabain‐resistant non‐small‐cell lung‐cancer CELL LINE SHOWS COLLATERAL SENSITIVITY TO cis‐diamminedichloroplatinum(II) (CDDP)

N. Saijo, K. Nishio, M. Adachi, 1994, International journal of cancer.

Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial.

K. Eguchi, K. Tominaga, N. Saijo, 1986, Japanese journal of clinical oncology.

[A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].

K. Eguchi, N. Saijo, Y. Sasaki, 1987, Gan to kagaku ryoho. Cancer & chemotherapy.

Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population

Teruhiko Yoshida, N. Saijo, Y. Goto, 2004, Human mutation.

Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells.

N. Saijo, K. Nishio, H. Kurokawa, 1999, Oncology reports.

The analysis of cytostatic activity of human peripheral blood granulocytes and its augmentation with Nocardia rubra cell wall skeleton (N-CWS)

M. Shibuya, N. Saijo, E. Shimizu, 2004, Journal of Cancer Research and Clinical Oncology.

Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin.

N. Saijo, Y. Fujiwara, K. Nishio, 1992, Cancer research.

Interleukin-2 gene transduction into freshly isolated lung adenocarcinoma cells with adenoviral vectors.

N. Saijo, Y. Heike, M. Takahashi, 1997, Human gene therapy.

The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitro.

N. Saijo, Y. Sasaki, K. Nakagawa, 1988, European journal of cancer & clinical oncology.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28

Teruhiko Yoshida, H. Ohmatsu, N. Saijo, 2007, Pharmacogenetics and genomics.

Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.

S. Hirohashi, Teruhiko Yoshida, N. Saijo, 2008, Cancer letters.

Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2008, Cancer Chemotherapy and Pharmacology.

Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer : Long-term follow-up results

N. Saijo, M. Fukuoka, K. Kubota, 2005 .

Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.

Y. Sugiyama, Teruhiko Yoshida, N. Saijo, 2003, Drug metabolism and pharmacokinetics.

Advances in Personalized Therapy for Lung Cancer

N. Saijo, 2011 .

Correlation of Gene‐specific Damage with Cisplatin between Human Adenocarcinoma Cells and Peripheral Blood Mononuclear Cells Analyzed by Polymerase Chain Reaction‐stop Assay

N. Saijo, H. Arioka, Y. Heike, 1995, Japanese journal of cancer research : Gann.

Rapid Polymerase Chain Reaction Assay to Detect Variation in the Extent of Gene‐specific Damage between Cisplatin‐ or VP‐16‐resistant and Sensitive Lung Cancer Cell Lines

N. Saijo, F. Oshita, 1994, Japanese journal of cancer research : Gann.

In vitro Enhancement of Antitumor Activity of a Water‐soluble Duocarmycin Derivative, KW‐2189, by Caffeine‐mediated DNA‐repair Inhibition in Human Lung Cancer Cells

N. Saijo, K. Nishio, H. Arioka, 1997, Japanese journal of cancer research : Gann.

Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.

N. Saijo, Y. Fujiwara, L. Liu, 1990, Cancer research.

Once weekly epoetin beta to increase hemoglobin and improve quality of life in anemic cancer patients receiving chemotherapy: A randomized, double-blind, dose-finding study

N. Saijo, Y. Ohashi, H. Sakai, 2004 .

Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer.

R. Kakinuma, N. Saijo, Y. Nishiwaki, 2001, Japanese journal of clinical oncology.

hnRNP L enhances sensitivity of the cells to KW‐2189

K. Yano, H. Kato, N. Saijo, 2004, International journal of cancer.

Proximal 5'-flanking sequence of the human gamma-glutamylcysteine synthetase heavy subunit gene is involved in cisplatin-induced transcriptional up-regulation in a lung cancer cell line SBC-3.

J. Usuda, N. Saijo, K. Nishio, 1997, Biochemical and biophysical research communications.

Identification ofcis-Acting DNA Elements of the Human γ-Glutamylcysteine Synthetase Heavy Subunit Gene

N. Saijo, K. Nishio, H. Arioka, 1997 .

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.

N. Saijo, K. Nishio, H. Fukumoto, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

The impact of an independent response evaluation committee (REC) using RECIST guidelines in a Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC) in Japan.

K. Mori, N. Saijo, Y. Nishiwaki, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drug Accumulation and Efflux Do not Contribute to Acquired Gefitinib Resistance

N. Saijo, K. Nishio, T. Kuroki, 2009 .

AZD 2171 Shows Potent AntitumorActivityAgainst Gastric Cancer OverExpressing Fibroblast Growth Factor Receptor 2 / Keratinocyte Growth Factor Receptor

N. Saijo, K. Nishio, K. Fukuoka, 2007 .

Restoration of p53 gene function in 12-O-tetradecanoylphorbor 13-acetate-resistant human leukemia K562/TPA cells.

J. Usuda, H. Kato, N. Saijo, 2003, International journal of oncology.

A randomized phase III study of irinotecan and cisplatin (CP) versus etoposide and cisplatin (EP) in extensive-disease small-cell lung cancer (ED-SCLC): Japan Clinical Oncology Group Study (JCOG 9511)

K. Mori, N. Saijo, Y. Nishiwaki, 2000 .

Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer.

K. Mori, N. Saijo, Y. Nishiwaki, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Participation of poly(ADP-robose) polymerase in the drug sensitivity in human lung cancer cell lines

N. Saijo, H. Esumi, Mitsuko Matsutani, 2005, Journal of Cancer Research and Clinical Oncology.

Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer

K. Eguchi, N. Saijo, K. Nakada, 2004, Cancer Chemotherapy and Pharmacology.

Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer.

N. Saijo, Y. Nishiwaki, S. Yoneda, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

The antitumor activity of radiation therapy is reduced in patients with non-small-cell carcinoma of the lung refractory to chemotherapy.

N. Saijo, Y. Sasaki, M. Morita, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin.

N. Saijo, Y. Fujiwara, K. Nishio, 1990, British Journal of Cancer.

Characterization of an etoposide-resistant human ovarian cancer cell line

T. Ohira, N. Saijo, K. Nishio, 2004, Cancer Chemotherapy and Pharmacology.

Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB.

N. Saijo, K. Nishio, F. Kanzawa, 1995, Cancer research.

Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair.

N. Saijo, Y. Ohe, Y. Fujiwara, 1990, Cancer research.

[Effect of cisplatin on cell cycle regulators].

N. Saijo, K. Nishio, 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients

H. Ueno, Teruhiko Yoshida, N. Saijo, 2010, Clinical pharmacokinetics.

Japan Clinical Oncology Group (JCOG).

N. Saijo, M. Shimoyama, H. Fukuda, 1998, Japanese journal of clinical oncology.

Overcoming multi‐drug resistance using an intracellular anti‐MDR1 sFv

T. Tsuruo, N. Saijo, K. Kasono, 2001, International journal of cancer.

Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro.

K. Eguchi, N. Saijo, Y. Ohe, 1995, Cancer research.

A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer.

N. Saijo, N. Yamamoto, T. Tamura, 2001, Japanese journal of clinical oncology.

Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs

N. Saijo, Y. Ohe, Y. Fujiwara, 1989, Japanese journal of cancer research : Gann.

LEVELS OF GLUTATHIONES TRANSFERASE π mRNA IN HUMAN LUNG CANCER CELL LINES CORRELATE WITH THE RESISTANCE TO CISPLATIN AND CARBOPLATIN

J. Yokota, N. Saijo, Y. Fujiwara, 1988, Japanese journal of cancer research : Gann.

Glutathione homeostasis in human hepatic cells: overexpression of gamma-glutamylcysteine synthetase gene in cell lines resistant to buthionine sulfoximine, an inhibitor of glutathione synthesis.

N. Saijo, K. Kohno, T. Uchiumi, 1998, Biochemical and biophysical research communications.

A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)

N. Saijo, Y. Nishiwaki, T. Tamura, 2009, British Journal of Cancer.

A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811)

N. Saijo, Y. Nishiwaki, M. Nishio, 2009, British Journal of Cancer.

6560 POSTER Prognostic factors affecting survival on pretreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) – Subgroup analysis in a randomized Ph II study of pemetrexed 500 mg/m2 and 1000 mg/m2

N. Saijo, Y. Nishiwaki, M. Fukuoka, 2007 .

A randomized phase II study of 500 mg/m2 and 1,000 mg/m2 of pemetrexed in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had prior chemotherapy

N. Saijo, Y. Ichinose, Y. Nishiwaki, 2007 .

In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2)

N. Saijo, Y. Sasaki, M. Sakurai, 2004, Journal of Cancer Research and Clinical Oncology.

Reduction of pulmonary metastases of B16 melanoma by human recombinant interleukin 2 and lymphokine-activated killer cells in immunosuppressed C57BL/6 mice receiving anticancer agent.

N. Saijo, A. Hamburger, Y. Sasaki, 1986, Japanese journal of cancer research : Gann.

Clonogenic cell assay for carcinoma of the lung.

N. Miyazawa, N. Saijo, E. Shimizu, 1984, Gan.

Apoptosis induced by etoposide in small-cell lung cancer cell lines

N. Saijo, K. Nishio, Y. Heike, 2004, Cancer Chemotherapy and Pharmacology.

Haplotype structures of the UGT1A gene complex in a Japanese population

N. Saijo, N. Kamatani, K. Kubota, 2006, The Pharmacogenomics Journal.

Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2009, Drug metabolism and pharmacokinetics.

SNP Communication Genetic Variations and Haplotype Structures of the Glutathione S-transferase Genes , GSTT 1 and GSTM 1 , in a Japanese Patient Population

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2009 .

Preferential Binding of E7010 to Murine β3‐Tubulin and Decreased β3‐Tubulin in E7010‐resistant Cell Lines

N. Saijo, K. Nishio, H. Fukumoto, 1998, Japanese journal of cancer research : Gann.

In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines

N. Saijo, Y. Ohe, Y. Fujiwara, 2004, Cancer Chemotherapy and Pharmacology.

Docetaxel (D) consolidation therapy following cisplatin (P), vinorelbine (V) and concurrent thoracic radiotherapy (TRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC)

K. Mori, N. Saijo, Y. Nishiwaki, 2005 .

Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion.

N. Saijo, K. Furuse, H. Kunitoh, 1998, British Journal of Cancer.

P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors

N. Saijo, T. Tamura, Y. Sasaki, 2003 .

Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by cis-diamminedichloroplatinum(II).

N. Saijo, Y. Fujiwara, K. Nishio, 1992, The Journal of clinical investigation.

Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes

K. Eguchi, N. Saijo, Y. Ohe, 1996, Cancer Chemotherapy and Pharmacology.

Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer.

K. Eguchi, K. Tominaga, N. Saijo, 1985, Cancer treatment reports.

Human metallothionein isoform gene expression in cisplatin-sensitive and resistant cells.

N. Saijo, R. Bahnson, J. Lazo, 1994, Molecular pharmacology.

Cytogenetic effect of carboplatin on human lymphocytes

K. Eguchi, N. Saijo, T. Nakajima, 1988, Cancer Chemotherapy and Pharmacology.

Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity

K. Eguchi, K. Suemasu, N. Saijo, 1989, Japanese journal of cancer research : Gann.

Cytogenetic effects of multiagent chemotherapy on the peripheral lymphocytes of patients with small cell lung cancer.

K. Eguchi, K. Tominaga, N. Saijo, 1986, Japanese journal of cancer research : Gann.

Molecular determinants of UCN‐01‐induced growth inhibition in human lung cancer cells

J. Usuda, H. Kato, N. Saijo, 2000, International journal of cancer.

Activation-Induced Apoptosis of Peripheral Lymphocytes Treated with 7-Hydroxystaurosporine, UCN-01

J. Usuda, N. Saijo, Y. Ohe, 1999, Investigational New Drugs.

Chemoradiation therapy in patients (pts) with small cell lung cancer (SCLC) with pericardial effusion but no distant metastasis.

H. Ohmatsu, N. Saijo, Y. Nishiwaki, 2009, Journal of Clinical Oncology.

Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.

N. Saijo, Y. Ohe, Y. Fujiwara, 1992, British Journal of Cancer.

In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line.

N. Saijo, K. Nishio, F. Kanzawa, 2003, Lung cancer.

Antitum or Activity of O xaliplatin, 5-FU and Paclitaxel G iven Alone or in Com bination with ZD 1839 in H um an Gastric Carcinom a Cells in vitro

N. Saijo, K. Nishio, Jin-Hyoung Kang, 2003 .

Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells

N. Saijo, S. Kudoh, K. Nishio, 1999, Cancer Chemotherapy and Pharmacology.

Chemotherapy: the more the better? Overview

N. Saijo, 1997, Cancer Chemotherapy and Pharmacology.

Suppression of natural killer activity in patients treated with cisplatin and methylprednisolone

K. Eguchi, K. Tominaga, N. Saijo, 2005, Journal of Cancer Research and Clinical Oncology.

Detection of cytotoxicity of freshly obtained lymphocytes and of lymphocytes activated with recombinant interleukin II (rIL-2) against lung cancer cell lines by human tumor clonogenic assay (HTCA).

N. Saijo, A. Hamburger, H. Futami, 1986, European journal of cancer & clinical oncology.

Ectopic p16ink4 expression enhances CPT‐11‐induced apoptosis through increased delay in S‐phase progression in human non‐small‐cell‐lung‐cancer cells

J. Usuda, N. Saijo, K. Nishio, 2000 .

Distal promoter regions are responsible for differential regulation of human orosomucoid-1 and -2 gene expression and acute phase responses.

N. Saijo, Yoshiro Saito, J. Sawada, 2014, Biological & pharmaceutical bulletin.

Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2011, Journal of pharmaceutical sciences.

Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid

N. Saijo, Y. Fujiwara, K. Kawashima, 2005, Journal of Cancer Research and Clinical Oncology.

Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS).

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2006, Drug metabolism and pharmacokinetics.

[Microtubules and antineoplastic drugs].

N. Saijo, H. Arioka, 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment].

Toshio Shimizu, N. Saijo, 2003, Nihon rinsho. Japanese journal of clinical medicine.

In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.

N. Saijo, T. Tamura, M. Iigo, 1988, Cancer research.

Paclitaxel-Induced Cell-Mediated Hypersensitivity Pneumonitis

N. Saijo, K. Fujimori, A. Yokoyama, 1998, Oncology.

Anticancer drug discovery and development throughout the world.

M. Ratain, N. Saijo, Y. Fujiwara, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-intensive chemotherapy in extensive-stage small-cell lung cancer

N. Saijo, M. Fukuoka, K. Furuse, 1997, Cancer Chemotherapy and Pharmacology.

Correlation B etween D ocetaxel C learance a nd E stimated Cytochrome P 450 A ctivity b y U rinary M etabolite o f Exogenous C ortisol

N. Saijo, T. Tamura, H. Kunitoh, 2000 .

In vitro chemosensitivity patterns of carcinoma of the lung in human tumor clonogenic assay.

K. Eguchi, N. Miyazawa, N. Saijo, 1986, Journal of pharmacobio-dynamics.

Correlation between drug sensitivity determined by clonogenic cell assay and clinical effect of chemotherapy in patients with primary lung cancer.

K. Eguchi, K. Tominaga, N. Saijo, 1984, Gan.

Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance.

N. Saijo, K. Nishio, H. Arioka, 1995, Biochemical and biophysical research communications.

A Randomized Cross‐over Study of High‐dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High‐dose Cisplatin

H. Ohmatsu, K. Eguchi, N. Saijo, 1994, Japanese journal of cancer research : Gann.

Effect of ACNU on primary lung cancer, mesothelioma, and metastatic pulmonary tumors.

N. Saijo, Y. Nishiwaki, I. Kawase, 1978, Cancer treatment reports.

A randomized phase II study of sequential carboplatin/paclitaxel (CP) and gefitinib (G) in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): Preliminary results.

N. Saijo, M. Kawaishi, N. Yamamoto, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Malignant germ cell tumor of the mediastinum: A multimodality therapeutic approach

R. Tsuchiya, H. Asamura, T. Naruke, 1994, Surgery Today.

Three novel single nucleotide polymorphisms in UGT1A9.

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2003, Drug metabolism and pharmacokinetics.

Three novel single nucleotide polymorphisms in UGT1A10.

Teruhiko Yoshida, H. Ohmatsu, R. Kakinuma, 2002, Drug metabolism and pharmacokinetics.

Contents Vol. 34, 2016

Y. Imai, M. Kudo, Y. Minami, 2016, Digestive Diseases.

Acquired factor VIII inhibitor in a patient with adenocarcinoma of the lung.

N. Saijo, T. Shigekiyo, A. Kojima, 1992, Japanese journal of clinical oncology.

Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant

Teruhiko Yoshida, N. Saijo, K. Muro, 2012, Immunogenetics.

Characterization of a Human Small‐cell Lung Cancer Cell Line Resistant to a New Water‐soluble Camptothecin Derivative, DX‐8951f

N. Saijo, K. Nishio, T. Ishida, 1998, Japanese journal of cancer research : Gann.

Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.

N. Saijo, M. Fukuda, Y. Ohe, 1995, Anticancer research.

Randomized phase III trial of carboplatin(C) plus etoposide (E) vs. split doses of cisplatin (P) plus etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): JCOG9702

N. Saijo, S. Kudoh, H. Kunikane, 2005 .

Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402.

N. Saijo, Y. Nishiwaki, Y. Ohe, 2010 .

Twenty-six novel single nucleotide polymorphisms and their frequencies of the NR1I3 (CAR) gene in a Japanese population.

Teruhiko Yoshida, N. Saijo, Y. Goto, 2003, Drug metabolism and pharmacokinetics.

Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis.

Teruhiko Yoshida, N. Saijo, K. Muro, 2010, Drug metabolism and pharmacokinetics.

A Novel Antitumor Antibiotic, KW‐2189 Is Activated by Carboxyl Esterase and Induces DNA Strand Breaks in Human Small Cell Lung Cancer Cells

T. Ohira, N. Saijo, K. Nishio, 1994, Japanese journal of cancer research : Gann.

The Mechanism of the Difference in Cellular Uptake of Platinum Derivatives in Non‐small Cell Lung Cancer Cell Line (PC‐14) and Its Cisplatin‐resistant Subline (PC‐14/CDDP)

N. Saijo, Y. Fujiwara, K. Nishio, 1993, Japanese journal of cancer research : Gann.

Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.

N. Saijo, Y. Fujiwara, K. Nishio, 1992, Journal of the National Cancer Institute.

Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.

K. Eguchi, N. Saijo, Y. Ohe, 1991, Cancer research.

Inhibitory effect of murine recombinant interferon (beta) on the pulmonary metastasis of B-16 melanoma.

J. Jett, N. Saijo, Y. Sasaki, 1986, Japanese journal of cancer research : Gann.

FUNCTIONAL CHARACTERIZATION OF THREE NATURALLY OCCURRING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CES2 GENE ENCODING CARBOXYLESTERASE 2 (HCE-2)

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2005, Drug Metabolism and Disposition.

Comparative study of the antitumor effect of two types of murine recombinant interferons, (β) and (γ), against B16-F10 melanoma

N. Saijo, Y. Ohe, T. Tamura, 2004, Cancer Immunology, Immunotherapy.

Mechanism of antitumor action of PKC activator, gnidimacrin

N. Saijo, H. Hidaka, T. Ikekawa, 1998, International journal of cancer.

A new MTT assay for examining the cytotoxicity of activated macrophages towards the non-adherent P388 leukaemia cell line.

N. Saijo, Y. Ohe, Y. Soejima, 1992, Journal of immunological methods.

Large cell carcinoma of the lung secreting human chorionic gonadotropin which responded to combination chemotherapy: case report.

R. Tsuchiya, N. Saijo, Y. Matsuno, 1990, Japanese journal of clinical oncology.

Primary lung cancer in an 18-year-old boy: case report.

N. Saijo, Y. Sasaki, M. Fukuda, 1990, Japanese journal of clinical oncology.

A case report of a three-year survivor with advanced non-small cell lung cancer producing alpha-fetoprotein.

K. Eguchi, N. Saijo, N. Keicho, 1986, Japanese journal of clinical oncology.

Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).

N. Saijo, Y. Nishiwaki, M. Ando, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study

N. Saijo, Y. Nishiwaki, M. Fukuoka, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by anti-asialo GMl antibody or anticancer agents

N. Saijo, E. Shimizu, Y. Sasaki, 2005, Journal of Cancer Research and Clinical Oncology.

In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay

N. Saijo, Y. Ohe, Y. Fujiwara, 2004, Cancer Chemotherapy and Pharmacology.

In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.

N. Saijo, Y. Lee, Y. Funayama, 1995, Cancer Research.

Characterization and Mechanism of Resistance Cell Line of Human Non-Small Cell Lung Cancer : Establishment of a Camptothecin Analogue ( CPT-11 )-resistant

N. Saijo, Y. Fujiwara, Y. Sugimoto, 2006 .

Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.

N. Saijo, Y. Fujiwara, K. Nishio, 1991, Cancer research.

Reversal of Cisplatin Resistance with Amphotericin B in a Non‐small Cell Lung Cancer Cell Line

N. Saijo, Y. Fujiwara, K. Nishio, 1991, Japanese journal of cancer research : Gann.

Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines.

N. Saijo, Y. Fujiwara, W. Hong, 1989, International journal of cancer.

In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model

N. Saijo, K. Nishio, K. Fukuoka, 1999, Cancer Chemotherapy and Pharmacology.

In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.

N. Saijo, Y. Ohe, Y. Fujiwara, 1989, Cancer research.

Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer

N. Saijo, M. Fukuoka, H. Kunikane, 2001, International Journal of Clinical Oncology.

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.

T. Mukohara, N. Saijo, M. Hirai, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.

Joon-Oh Park, P. Jänne, T. Mukohara, 2009, Cancer letters.

p16INK4 Expression Is Associated with the Increased Sensitivity of Human Non‐small Cell Lung Cancer Cells to DNA Topoisomerase I Inhibitors

J. Yokota, N. Saijo, H. Yokote, 1997, Japanese journal of cancer research : Gann.

Report of the Seventh International Symposium of the Foundation for Promotion of Cancer Research: fundamental and clinical research in lung cancer.

J. Yokota, A. Gazdar, N. Saijo, 1994, Japanese journal of clinical oncology.

Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

Koichi Goto, Masahiro Fukuoka, Nobuyuki Yamamoto, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study.

N. Saijo, Y. Ohashi, K. Sugihara, 2013, Japanese journal of clinical oncology.

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

M. Kudo, N. Saijo, K. Nishio, 2011, Molecular Cancer Therapeutics.

Adenovirus‐mediated p16 gene transfer prevents drug‐induced cell death through G1 arrest in human glioma cells

K. Kurisu, N. Saijo, D. Curiel, 1998 .

Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes.

M. Shibuya, J. Yokota, N. Saijo, 1991, British Journal of Cancer.

Novel Water-Soluble Derivatives of Docosahexaenoic Acid Increase Diacylglycerol Production Mediated by Phosphatidylcholine-Specific Phospholipase C

N. Saijo, K. Nishio, K. Yazawa, 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Masahiro Fukuoka, Haiyi Jiang, Kazuhiko Nakagawa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutational status of EGFR and KIT in thymoma and thymic carcinoma.

H. Ohmatsu, N. Saijo, Y. Nishiwaki, 2008, Lung cancer.

Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer.

K. Eguchi, N. Saijo, Y. Ohe, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Increased cytotoxic effects of photodynamic therapy in IL‐6 gene transfected cells via enhanced apoptosis

J. Usuda, H. Kato, T. Okunaka, 2001, International journal of cancer.

1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line.

N. Saijo, K. Nishio, Y. Iwamoto, 1996, Anticancer research.

9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes – Exploratory Data From IPASS

T. Mok, Yi-long Wu, S. Thongprasert, 2011 .

Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation

Y. Yatabe, T. Mitsudomi, N. Saijo, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer

A. Gemma, N. Saijo, Y. Nishiwaki, 2008, Cancer.

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.

H. Ohmatsu, R. Kakinuma, N. Saijo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models

Fumiaki Koizumi, N. Saijo, K. Nishio, 2004, Cancer science.

Effect of combination treatment with mitomycin-c and lysosome labilizers on nodular pulmonary metastases.

N. Saijo, I. Kawase, T. Taniguchi, 1974, Gan.

The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

N. Saijo, Y. Nishiwaki, Y. Ohe, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Alteration of Type II Regulatory Subunit of cAMP‐dependent Protein Kinase in Human Cisplatin‐resistant Cells as a Basis of Collateral Sensitivity to 8‐Chloro‐cAMP

N. Saijo, Y. Fujiwara, K. Nishio, 1992, Japanese journal of cancer research : Gann.

Prediction of hematologic toxicity of carboplatin by creatinine clearance rate.

K. Eguchi, N. Saijo, Y. Fujiwara, 1987, Japanese journal of cancer research : Gann.

Dose intensity of irinotecan (CPT) combined with weekly cisplatin (DDP) and etoposide (ETOP) in patients (pts) with metastatic lung cancer (LC): Phase I/II study JCOG 9507

H. Ohmatsu, R. Kakinuma, K. Eguchi, 2000 .

Antitumor action of the PKC activator gnidimacrin through cdk2 inhibition

N. Saijo, K. Nishio, H. Wakasugi, 2001, International journal of cancer.

The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification

J. Austin, A. Nicholson, I. Petersen, 2009 .

Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.

N. Saijo, Y. Ichinose, Y. Ohe, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Common arm comparative outcomes analysis of phase III trials of cisplatin + irinotecan vs. cisplatin + etoposide in extensive stage small cell lung cancer: Final patient-level results from JCOG 9511 and SWOG 0124

N. Saijo, D. Gandara, K. Chansky, 2011 .

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer 1

N. Saijo, D. Gandara, K. Chansky, 2010 .

Cooperative group research endeavors in small-cell lung cancer: current and future directions.

H. Choy, N. Saijo, D. Gandara, 2009, Clinical lung cancer.

Performance status and sensitivity to first‐line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second‐line chemotherapy

H. Ohmatsu, N. Saijo, Y. Nishiwaki, 2008, Cancer.

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer

K. Mori, N. Saijo, Y. Nishiwaki, 2008, British Journal of Cancer.

The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC).

N. Saijo, Y. Nishiwaki, Y. Ohe, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.

N. Saijo, K. Kubota, M. Nishio, 2014, The Lancet. Oncology.

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2003, Pharmacogenetics.

Enhancement of Epidermal Growth Factor Receptor-degradation Pathway in Acquired Gefitinib-resistant Human Non-small Cell Lung Cancer Cell Lines

M. Matsuda, N. Saijo, K. Nishio, 2004 .

UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer

Kazuo Komamura, Naoyuki Kamatani, Noriko Katori, 2004, Clinical pharmacology and therapeutics.

Recent development of molecular-targeted drugs in lung cancer.

N. Saijo, H. Kenmotsu, 2010, Internal medicine.

Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.

N. Saijo, Y. Fujiwara, K. Nishio, 1992, Biochemical and biophysical research communications.

Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma

T. Ohira, T. Yamanaka, N. Ikeda, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antitumor activity of the selective epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) Iressa® (ZD1839) in an EGFR‐expressing multidrug‐resistant cell line in vitro and in vivo

N. Saijo, M. Mori, K. Nishio, 2002, International journal of cancer.

Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2006, Drug metabolism and pharmacokinetics.

Close Association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 Haplotype and Its Apparent Influence on 7-Ethyl-10-hydroxycamptothecin (SN-38) Glucuronidation in Japanese

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2009, Drug Metabolism And Disposition.

Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2003, Journal of Pharmacology and Experimental Therapeutics.

Effects of β- and γ-carboline derivatives on DNA topoisomerase activities

T. Ohira, N. Saijo, K. Nishio, 1996 .

Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy.

H. Kato, N. Saijo, Y. Nishiwaki, 2006, Lung cancer.

Novel combination chemotherapy in the treatment of non-small cell lung cancer

N. Saijo, I. Sekine, Nagahiro Saijo, 2000, Expert opinion on pharmacotherapy.

The colony inhibition of a new chemotherapeutic agent (KW2152) against human lung cancer cell lines

J. Jett, K. Suemasu, N. Saijo, 2004, Investigational New Drugs.

Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan)

K. Eguchi, N. Saijo, Y. Fujiwara, 2004, Journal of Cancer Research and Clinical Oncology.

A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy

K. Eguchi, N. Saijo, Y. Ohe, 2004, Cancer Chemotherapy and Pharmacology.

A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.

K. Eguchi, N. Saijo, Y. Ohe, 1991, European journal of cancer.

Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin.

K. Eguchi, K. Tominaga, N. Saijo, 1986, Japanese journal of cancer research : Gann.

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer

M. Tsuboi, K. Eguchi, N. Saijo, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6

N. Saijo, Y. Ohe, K. Nishio, 2001, Japanese journal of cancer research : Gann.

Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma

T. Ohira, T. Yamanaka, N. Ikeda, 2010, Clinical Cancer Research.

A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancer.

N. Saijo, Y. Nishiwaki, Y. Ohe, 2001, Lung Cancer.

A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer

N. Saijo, C. Shimizu, K. Nishio, 2009, International Journal of Clinical Oncology.

A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer

J. Minna, N. Saijo, K. Nishio, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Retrospective Analysis of Safety and Efficacy of Low-Dose Docetaxel 60 mg/m2 in Advanced Non–Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy

N. Saijo, K. Kubota, T. Tamura, 2003, American journal of clinical oncology.

The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology

N. Saijo, 2012, Yonsei medical journal.

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

J. Crowley, C. Coltman, H. McLeod, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812).

N. Saijo, T. Tamura, N. Ishizuka, 2005, Japanese journal of clinical oncology.

Comparative studies of pulse and continuous exposure in human tumor clonogenic assay.

N. Saijo, Y. Sasaki, K. Nakagawa, 1987, Journal of pharmacobio-dynamics.

Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study

A. Gemma, N. Saijo, N. Miyanaga, 2020, Japanese journal of clinical oncology.

Problems involved in the clinical trials for non-small cell lung carcinoma.

N. Saijo, 2012, Cancer treatment reviews.

Developments for a growing Japanese patient population: facilitating new technologies for future health care.

Fumio Nomura, Tadashi Kondo, Toshihide Nishimura, 2011, Journal of proteomics.

act of Serum Hepatocyte Growth Factor on Treatment ponse to Epidermal Growth Factor Receptor Tyrosine ase Inhibitors in Patients with Non–Small Cell

T. Ohira, N. Ikeda, N. Saijo, 2010 .

Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.

N. Saijo, 2012, Cancer treatment reviews.

Growth-stimulating pathways in lung cancer: implications for targets of therapy.

N. Saijo, I. Sekine, 2001, Clinical lung cancer.

BiomarkerAnalysesandFinalOverallSurvivalResultsFroma PhaseIII,Randomized,Open-Label,First-LineStudyofGefitinib VersusCarboplatin/PaclitaxelinClinicallySelectedPatientsWith AdvancedNon-Small-CellLungCancerinAsia(IPASS)

T. Mok, Yi-long Wu, S. Thongprasert, 2011 .

Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).

T. Mok, Yi-long Wu, N. Saijo, 2014, Lung cancer.

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.

Jie Yang, T. Mok, Yi-long Wu, 2013, Lung cancer.

未治療の非小細胞肺癌患者に対するゲフィチニブとカルボプラチン・パクリタキセルの第III相国際共同試験（IPASS）の全生存期間最終解析

N. Saijo, Y. Ichinose, Y. Nishiwaki, 2012 .

Targeted therapies: Tyrosine-kinase inhibitors—new standard for NSCLC therapy

N. Saijo, 2010, Nature Reviews Clinical Oncology.

Impact of Serum HGF on Treatment Response to EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Adenocarcinoma

T. Ohira, N. Ikeda, N. Saijo, 2010 .

Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients.

N. Saijo, Y. Ohe, T. Tamura, 2006, Japanese journal of clinical oncology.

Epoetin Beta Subcutaneous Administration to Lung Cancer Patients with Anemia; Results of Pharmacokinetics/Pharmacodynamics Study

N. Saijo, M. Fukuoka, T. Satoh, 2007 .

The value of two‐dimensional echocardiography in detecting malignant tumors in the heart

K. Eguchi, K. Tominaga, N. Saijo, 1986, Cancer.

Enhanced interaction between tubulin and microtubule‐associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel

N. Saijo, H. Arioka, H. Kurokawa, 1995, International journal of cancer.

Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474

N. Saijo, K. Nishio, H. Fukumoto, 2004, Cancer Research.

Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9, PC-13 and PC-14) and how they influence the results of test for chemosensitivity to cisplatin in the human tumor clonogenic assay.

N. Saijo, A. Hamburger, Y. Sasaki, 1985, Japanese journal of clinical oncology.

Cardiac tamponade caused by primary lung cancer and the management of pericardial effusion

N. Saijo, M. Yamakido, T. Shinkai, 1993, Cancer.

Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.

K. Eguchi, N. Saijo, Y. Ohe, 1994, Japanese journal of clinical oncology.

Reply to ‘Malignant pericardial effusion: sclerotherapy or local chemotherapy?’

N. Saijo, T. Tamura, H. Kunitoh, 2009, British Journal of Cancer.

Enhancement of Sensitivity to Tumor Necrosis Factor α in Non–Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib

N. Saijo, K. Nishio, T. Kuroki, 2005, Clinical Cancer Research.

CIS‐diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung‐cancer cells

T. Ohira, N. Saijo, Y. Fujiwara, 1993, International journal of cancer.

Characterisation of a vindesine-resistant human small-cell lung cancer cell line.

N. Saijo, K. Nishio, M. Nishio, 1993, British Journal of Cancer.

Present Status and Problems on Molecular Targeted Therapy of Cancer

N. Saijo, 2012, Cancer research and treatment : official journal of Korean Cancer Association.

Haplotypes and a Novel Defective Allele of CES2 Found in a Japanese Population

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2007, Drug Metabolism and Disposition.

Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.

N. Saijo, Y. Ichinose, Y. Ohe, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Guidelines for Analysis and Reporting of Clinical Trials in Oncology

S. Piantadosi, N. Saijo, T. Tamura, 1993, Japanese journal of cancer research : Gann.

Detailed structural analysis on both human MRP5 and mouse mrp5 transcripts.

N. Saijo, K. Nishio, H. Kuh, 2000, Gene.

A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.

N. Saijo, M. Fukuoka, M. Takada, 2009, Japanese journal of clinical oncology.

Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).

N. Saijo, Y. Ohe, N. Yamamoto, 2012, The Lancet. Oncology.

Phase II study of cis-diamminedichloroplatinum in patients with non-small cell lung cancer.

K. Eguchi, K. Tominaga, N. Saijo, 1985, Japanese journal of cancer research : Gann.

AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor

N. Saijo, H. Yokote, K. Nishio, 2007, Clinical Cancer Research.

Advances in the treatment of non-small cell lung cancer.

N. Saijo, 2008, Cancer treatment reviews.

A randomised phase II trial of preoperative chemotherapy of cisplatin–docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204)

M. Tsuboi, M. Okada, H. Asamura, 2008, British Journal of Cancer.

Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2010, British journal of clinical pharmacology.

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507

H. Ohmatsu, R. Kakinuma, K. Eguchi, 2003, British Journal of Cancer.

Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.

N. Saijo, S. Kusumoto, T. Hirose, 2009, Anticancer research.

Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment*

Yoshiro Saito, Hideki Ueno, Koh Furuta, 2010, Molecular & Cellular Proteomics.

Combination effect of vaccination with IL2 and IL4 cdna transfected cells on the induction of a therapeutic immune response against lewis lung carcinoma cells

T. Ohira, N. Saijo, Y. Ohe, 1993, International journal of cancer.

Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.

K. Eguchi, N. Saijo, Y. Fujiwara, 1989, Cancer research.

A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies

N. Laird, H. Ueno, N. Saijo, 2009, The Pharmacogenomics Journal.

Colony Inhibitory Effect of Recombinant Human Tumor Necrosis Factor (rH-TNF) and/or Recombinant Human Interferon (rH-IFN)-α -β and -γ on Human Lung Cancer Cell Lines

J. Jett, N. Saijo, W. Hong, 1987 .

Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta and -gamma on human lung cancer cell lines.

J. Jett, N. Saijo, W. Hong, 1987, Japanese journal of clinical oncology.

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.

M. Kusumoto, N. Saijo, Y. Ohe, 2004, Lung cancer.

A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)

N. Saijo, Y. Nishiwaki, T. Tamura, 2010, British Journal of Cancer.

Decreased expression of alpha2,8 sialyltransferase and increased expression of beta1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers.

N. Saijo, K. Nishio, H. Fukumoto, 2002, Experimental biology and medicine.

Culture of retinoblastoma cells from clinical specimens: growth-promoting effect of 2-Mercaptoethanol

N. Saijo, S. Tokura, A. Kaneko, 2005, Journal of Cancer Research and Clinical Oncology.

Prediction from Creatinine Clearance of Thrombocytopenia and Recommended Dose in Patients Receiving (Glycolato‐O, O′)‐diammine Platinum (II) (NSC 375101D)

K. Eguchi, N. Saijo, Y. Ohe, 1990, Japanese journal of cancer research : Gann.

Rationale for the combination therapy of 5FU and CDDP.

N. Saijo, Y. Sugirnoto, Yoshikazu Sugirnoto, 1993, Advances in experimental medicine and biology.

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma

N. Saijo, Y. Ohe, N. Yamamoto, 2004, British Journal of Cancer.

A bioassay of cisplatin by human tumor clonogenic assay.

N. Saijo, Y. Sasaki, J. Ishihara, 1986, Japanese journal of cancer research : Gann.

The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.

J. Jett, K. Eguchi, N. Saijo, 1986, Japanese journal of clinical oncology.

Y/6 chromosome translocation in a male with triple primary cancers involving the breast

N. Saijo, M. Noguchi, T. Shinkai, 2005, Journal of Cancer Research and Clinical Oncology.

Enhancement of Cisplatin Sensitivity in High Mobility Group 2 cDNA‐transfected Human Lung Cancer Cells

Kazuya Fukuoka, N. Saijo, H. Yokote, 1999, Japanese journal of cancer research : Gann.

Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial.

K. Eguchi, N. Saijo, Y. Ohe, 1989, Japanese journal of clinical oncology.

Indirect‐response model for the time course of leukopenia with anticancer drugs

N. Saijo, K. Itoh, Y. Sasaki, 1998, Clinical pharmacology and therapeutics.

Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.

N. Saijo, H. Arioka, T. Ishida, 1996, Cancer research.

Characterization of an etoposide-resistant human small-cell lung cancer cell line

N. Saijo, Y. Fujiwara, K. Nishio, 2008, Cancer Chemotherapy and Pharmacology.

Differential macrophage-mediated cytotoxicity to P388 leukemia cells and its drug-resistant cells examined by a new MTT assay.

N. Saijo, Y. Ohe, K. Miura, 1992, Leukemia research.

Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC).

N. Saijo, Y. Nishiwaki, Y. Ohe, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer

H. Ohmatsu, R. Kakinuma, N. Saijo, 2004, British Journal of Cancer.

Pilot Study of Concurrent Etoposide and Cisplatin Plus Accelerated Hyperfractionated Thoracic Radiotherapy Followed by Irinotecan and Cisplatin for Limited-Stage Small Cell Lung Cancer: Japan Clinical Oncology Group 9903

K. Mori, N. Saijo, Y. Nishiwaki, 2005, Clinical Cancer Research.

Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.

N. Saijo, Y. Ohe, Hirokazu Watanabe, 2003, Japanese journal of clinical oncology.

Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes.

N. Saijo, T. Shinkai, A. Kojima, 1993, Japanese journal of clinical oncology.

Experimental and clinical effect of ACNU in Japan, with emphasis on small-cell carcinoma of the lung

N. Saijo, H. Niitani, 2004, Cancer Chemotherapy and Pharmacology.

Antitumor effect of two-drug simultaneous or sequential use of cisplatin, vindesine or etoposide on human pulmonary adenocarcinoma cell lines in tumor clonogenic assay.

N. Saijo, A. Hamburger, Y. Sasaki, 1986, Japanese journal of cancer research : Gann.

[Current perspectives in the management of non-small cell lung cancer].

N. Saijo, J. Fujita, 1985, Gan no rinsho. Japan journal of cancer clinics.

Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?

H. Ohmatsu, R. Kakinuma, N. Saijo, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK).

H. Ueno, Teruhiko Yoshida, N. Saijo, 2008, Drug metabolism and pharmacokinetics.

The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function

K. Eguchi, N. Saijo, Y. Ohe, 2004, Cancer Chemotherapy and Pharmacology.

Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel

Yasunori Sato, Noriko Katori, Hiromi Sakamoto, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10.

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2003, Drug metabolism and disposition: the biological fate of chemicals.

DIFFERENTIATION OF Ca 2+ SIGNALLING BETWEEN ADRIAMYCIN-SENSITIVE AND RESISTANT CELL LINES OF HUMAN LUNG CANCER, SBC-3

T. Kanno, N. Saijo, T. Ishida, 1996 .

Molecularly Targeted Therapy for Lung Cancer: Recent Topics

N. Saijo, 2008 .

Progress in cancer chemotherapy with special stress on molecular-targeted therapy.

N. Saijo, 2010, Japanese Journal of Clinical Oncology.

In vivo and in vitro effects of Nocardia rubra cell wall skeleton on natural killer activity in mice.

M. Shibuya, N. Saijo, T. Taniguchi, 1983, Gan.

Enzyme activities in spleen lymphocytes of tumor-bearing rats, and effect of Propionibacterium acnes, BCG, and toxohormone on the enzyme activities in spleen lymphocytes of rats.

N. Saijo, I. Kawase, T. Taniguchi, 1981, Cellular and molecular biology, including cyto-enzymology.

Effect of Propionibacterium acnes or BCG on enzyme activities in spleen lymphocytes of Donryu strain rats.

N. Saijo, T. Taniguchi, H. Niitani, 1978, Gan.

Changes of enzyme activities in spleen lymphocytes from tumor-bearing rats.

N. Saijo, I. Kawase, T. Taniguchi, 1975, Gan.

Combined effect of BCG and coenzyme Q10 on ATP-ase activity and coenzyme Q content in spleen lymphocytes of tumor-bearing rats.

N. Saijo, I. Kawase, T. Taniguchi, 1979, Gan.

Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515.

N. Saijo, M. Fukuoka, S. Kudoh, 2007, Lung cancer.

Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small Cell Lung Cancer

K. Mori, N. Saijo, Y. Nishiwaki, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).

T. Nakano, K. Mori, N. Saijo, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer.

K. Mori, N. Saijo, M. Fukuoka, 2002, Lung cancer.

A phase II trial of low-dose docetaxel (DCT) 60 mg/m2 in platinum-pretreated advanced non-small cell lung cancer (NSCLC)

Yusuke Nakamura, N. Saijo, Y. Ohe, 2000 .

Emerging ethnic differences in lung cancer therapy

N. Saijo, K. Nishio, N. Yamamoto, 2008, British Journal of Cancer.

The development and clinical use of a beam ON-LINE PET system mounted on a rotating gantry port in proton therapy.

Keiichi Nakagawa, Teiji Nishio, N. Saijo, 2008, International journal of radiation oncology, biology, physics.

Jie Yang, Yi-long Wu, S. Thongprasert, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Heregulin as a novel cetuximab-resistace factor in colorectal cancer.

P. Jänne, N. Saijo, M. Fukuoka, 2010 .

Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207†.

N. Saijo, Y. Ohe, M. Ando, 2015, Japanese journal of clinical oncology.

Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer

N. Saijo, Y. Ichinose, Y. Nishiwaki, 2008, Clinical Cancer Research.

Efficacy and Safety ofTwo Doses of Pemetrexed Supplemented with Folic Acid andVitamin B 12 in PreviouslyTreated Patients with Non-Small Cell Lung Cancer

N. Saijo, Y. Ichinose, Y. Nishiwaki, 2008 .

Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy

K. Eguchi, K. Tominaga, K. Suemasu, 1986, Cancer.

Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma.

D. Beer, I. Wistuba, N. Saijo, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma

M. Kudo, Y. Minami, S. Hagiwara, 2016, Digestive Diseases.

Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type.

A. Gemma, T. Yamanaka, N. Saijo, 2010, Anticancer research.

Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer.

H. Choy, H. Wakelee, N. Saijo, 2008, Clinical lung cancer.

A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2.

Young Hak Kim, H. Ohmatsu, N. Saijo, 2009, Japanese Journal of Clinical Oncology.

Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402).

N. Saijo, Y. Ichinose, M. Fukuoka, 2012 .

[Induction of tumor immunity by cytokine cDNA transfected Lewis lung carcinoma].

N. Saijo, Y. Ohe, T. Ohira, 1992, Nihon Kyobu Shikkan Gakkai zasshi.

Genetic polymorphisms of UGT1A6 in a Japanese population.

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2005, Drug metabolism and pharmacokinetics.

Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl.

N. Saijo, T. Kuroki, T. Nakadate, 2007, Anticancer research.

Randomized phase II study of cisplatin , irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer ( JCOG 9902-DI )

T. Nakano, N. Saijo, Y. Nishiwaki, 2003 .

Cisplatin plus oral etoposide in the treatment of patients with advanced small cell lung cancer. Japan Clinical Oncology Group.

N. Saijo, K. Furuse, T. Tamura, 1998, Japanese journal of clinical oncology.

Factors that influence the eligibility of cases for inclusion in clinical trials. The Lung Cancer Chemotherapy Study Group of the Japan Clinical Oncology Group.

N. Saijo, K. Kubota, N. Yamamoto, 1998, Japanese journal of clinical oncology.

Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions

K. Eguchi, N. Saijo, Y. Ohe, 1995, Japanese journal of cancer research : Gann.

Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay

N. Miyazawa, N. Saijo, E. Shimizu, 2004, Investigational New Drugs.

Preclinical and Clinical Trials of Topoisomerase Inhibitors

N. Saijo, 2000, Annals of the New York Academy of Sciences.

A new antitumor antibiotic FR66973: clonogenic in vitro assessment of activity against human non-small cell lung carcinoma

K. Eguchi, R. Tsuchiya, N. Saijo, 1987, Investigational New Drugs.

[In vitro antitumor activity of 7-N-(p-hydroxyphenyl)-mitomycin C (KW-2083) against cultured bronchogenic carcinoma cells (PC-7)].

M. Shibuya, N. Saijo, E. Shimizu, 1983, Gan no rinsho. Japan journal of cancer clinics.

[Phase II study of KW2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with carcinoma of the lung and metastatic pulmonary tumor].

M. Shibuya, K. Eguchi, K. Tominaga, 1983, Gan to kagaku ryoho. Cancer & chemotherapy.

Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A).

H. Katayama, N. Saijo, M. Ando, 2021, Japanese journal of clinical oncology.

Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer.

N. Saijo, I. Sekine, M. Sumi, 2008, The oncologist.

Platinum-based chemotherapy with or without thoracic radiation therapy in patients with unresectable thymic carcinoma.

N. Saijo, K. Kubota, S. Kohno, 2000, Japanese journal of clinical oncology.

Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay

N. Saijo, E. Shimizu, Y. Sasaki, 2004, Cancer Chemotherapy and Pharmacology.

Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion

H. Ohmatsu, N. Saijo, Y. Nishiwaki, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer

Hironobu Ohmatsu, Shigeru Nawano, Koji Murakami, 2007 .

Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.

K. Eguchi, N. Saijo, Y. Ohe, 1995, Japanese journal of clinical oncology.

Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806.

H. Kato, M. Tsuboi, H. Asamura, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhancing effect of coenzyme, Q10 on immunorestoration with Mycobacterium bovis BCG in tumor-bearing mice.

N. Saijo, I. Kawase, H. Niitani, 1978, Gan.

Concurrent Chemoradiotherapy with Cisplatin and Vinorelbine for Stage III Non-small Cell Lung Cancer

H. Ohmatsu, N. Saijo, Y. Nishiwaki, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells

N. Saijo, K. Nishio, Jin-Hyoung Kang, 2004, Anti-cancer drugs.

Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non‐small cell lung cancer

N. Saijo, Y. Ohe, T. Tamura, 2004, Cancer science.

Adenovirus-mediated p16 gene transfer prevents drug-induced cell death through G1 arrest in human glioma cells.

K. Kurisu, N. Saijo, D. Curiel, 1998, International journal of cancer.

A Multi-Institution Phase I/II Trial of Triweekly Regimen with S-1 Plus Cisplatin in Patients with Advanced Non-small Cell Lung Cancer

N. Saijo, Y. Ichinose, M. Fukuoka, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dimerization and the signal transduction pathway of a smallin‐frame deletion in the epidermal growth factor receptor

N. Saijo, K. Nishio, T. Tamura, 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients.

H. Ohmatsu, R. Kakinuma, N. Saijo, 2001, Japanese journal of clinical oncology.

Increased phosphorylation of nuclear phosphoproteins in human lung‐cancer cells resistant to cis‐diamminedichloroplatinum(II)

N. Saijo, Y. Fujiwara, Y. Sugimoto, 1992, International journal of cancer.

Recurrence of thymoma with appearance of myasthenia gravis 18 years after surgery: a case report.

H. Hasegawa, N. Miyazawa, N. Saijo, 1985, Japanese journal of clinical oncology.

Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW‐2189 in Cell Lines Resistant to Cisplatin and CPT‐11

T. Ohira, N. Saijo, K. Nishio, 1995, Japanese journal of cancer research : Gann.

[A summary report of response evaluation criteria in solid tumors (RECIST criteria)].

N. Saijo, H. Kusaba, 2000, Gan to kagaku ryoho. Cancer & chemotherapy.

Effects of BCG and 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) on the cytostatic activity of macrophages in normal and tumour-bearing rats.

N. Saijo, E. Shimizu, H. Niitani, 1980, British Journal of Cancer.

Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.

H. Choy, H. Wakelee, B. Loo, 2009, Clinical lung cancer.

Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy.

H. Ohmatsu, R. Kakinuma, N. Saijo, 2007, Lung cancer.

Antitumor activity of daphnane‐type diterpene gnidimacrin isolated from Stellera chamaejasme L

N. Saijo, T. Ikekawa, W. Feng, 1996, International journal of cancer.

Phase II study of twice-daily high-dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non-small-cell lung cancer: Japan Clinical Oncology Group Study 9306.

K. Mori, N. Saijo, Y. Nishiwaki, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).

K. Mori, N. Saijo, Y. Ohe, 2001, Japanese journal of clinical oncology.

Phorbol ester and okadaic acid-resistant cells: the crossroads of signal transduction and drug resistance.

N. Saijo, K. Nishio, H. Arioka, 1995, The American journal of medicine.

Preface for JCOG review series.

N. Saijo, 2011, Japanese journal of clinical oncology.

A Limited Sampling Model for Estimating Pharmacokinetics of CPT‐11 and Its Metabolite SN‐38

N. Saijo, K. Itoh, Y. Sasaki, 1995, Japanese journal of cancer research : Gann.

Genetic variations and haplotypes of UGT1A4 in a Japanese population.

Teruhiko Yoshida, N. Saijo, N. Kamatani, 2005, Drug metabolism and pharmacokinetics.

D256N, found in Japanese cancer patients

Teruhiko Yoshida, N. Saijo, Yoshiro Saito, 2003 .

Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial.

N. Saijo, Y. Nishiwaki, Y. Kawakami, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetic Study of Mitomycin C with Emphasis on the Influence of Aging

N. Saijo, Y. Sasaki, A. Karato, 1992, Japanese journal of cancer research : Gann.

In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model.

N. Saijo, F. Kanzawa, 1997, Seminars in oncology.

Slug Increases Sensitivity To Tubulin Binding Agents Via The Downregulation Of Beta III And IVa-Tubulin In Lung Cancer Cells

W. Nishio, N. Saijo, K. Nishio, 2012, ATS 2012.

P3-148: Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non–small cell lung cancer (NSCLC); integrated analysis of two Japanese phase II studies

N. Saijo, Y. Ichinose, Y. Nishiwaki, 2007 .

Novel genetic polymorphisms in the NR3C1 (glucocorticoid receptor) gene in a Japanese population.

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2005, Drug metabolism and pharmacokinetics.

Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo

M. Kudo, N. Saijo, Kaoru Tanaka, 2010, Clinical Cancer Research.

Up-regulated gene expression of angiogenesis factors in post-chemotherapeutic lung cancer tissues determined by cDNA macroarray.

J. Usuda, H. Kato, T. Ohira, 2002, Oncology reports.

Genetic Variations and Haplotype Structures of the ABCB1 Gene in a Japanese Population: An Expanded Haplotype Block Covering the Distal Promoter Region, and Associated Ethnic Differences

N. Saijo, Y. Ohe, N. Kamatani, 2006, Annals of human genetics.

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients

H. Ueno, N. Saijo, M. Ikeda, 2009, British Journal of Cancer.

Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.

N. Saijo, Y. Fujiwara, Y. Ohashi, 2008, Japanese journal of clinical oncology.

CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2007, Pharmacogenetics & Genomics.

Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.

N. Saijo, K. Kiura, M. Tanimoto, 2006, Lung cancer.

Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOG0207

N. Saijo, Y. Nishiwaki, Y. Ohe, 2007 .

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

N. Saijo, Y. Nishiwaki, Haiyi Jiang, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells

N. Saijo, Y. Koh, T. Tamura, 2001, Cancer.

Clinical features and the results of treatment of brain metastases in small cell lung cancer.

K. Eguchi, N. Saijo, Y. Ohe, 1990 .

A retrospective analysis of patients receiving surgery after chemotherapy for small cell lung cancer.

K. Eguchi, N. Saijo, Y. Ohe, 1991, Japanese journal of clinical oncology.

Combined modality therapy for small cell lung cancer.

N. Saijo, 1992, Oncology.

Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2009, Drug Metabolism and Pharmacokinetics.

Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age

N. Saijo, K. Furuse, I. Sekine, 2000, Cancer Chemotherapy and Pharmacology.

Cancer Cell Lines : Relation to DNA Damage and Repair-Diamminedichloroplatinum ( II ) in Human Non-Small Cell Lung cis Decreased Accumulation as a Mechanism of Resistance to Updated

N. Saijo, Y. Ohe, Y. Sasaki, 2006 .

Intradural parenchymal involvement in the spinal subarachnoid space associated with primary lung cancer

N. Saijo, Y. Matsuno, T. Shinkai, 1993, Cancer.

Correlation between total dose of cisplatin and vibratory perception thveshold in chemotherapy-induced peripheral neuropathy of cancer patients

S. Piantadosi, H. Ohmatsu, K. Eguchi, 1992 .

[Clinical trial of IL-12 for cancer patients].

N. Saijo, Y. Heike, Y. Ohe, 1998, Gan to kagaku ryoho. Cancer & chemotherapy.

Detection of Proteins that Recognize Platinum‐modified DNA Using Gel Mobility Shift Assay

N. Saijo, Y. Fujiwara, K. Nishio, 1990, Japanese journal of cancer research : Gann.

Translational and clinical studies of target-based cancer therapy

N. Saijo, K. Nishio, T. Tamura, 2003, International Journal of Clinical Oncology.

Problems in the development of target-based drugs

N. Saijo, K. Nishio, T. Tamura, 2000, Cancer Chemotherapy and Pharmacology.

Gene Expression Profiling of Exposure to TZT-1027, a Novel Microtubule-Interfering Agent, in Non-Small Cell Lung Cancer PC-14 Cells and Astrocytes

N. Saijo, K. Nishio, T. Natsume, 2004, Investigational New Drugs.

Strategy for the development of novel anticancer drugs

N. Saijo, K. Nishio, T. Tamura, 2003, Cancer Chemotherapy and Pharmacology.

Translational study in cancer research.

N. Saijo, 2002, Internal medicine.

Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer.

N. Saijo, Y. Ohe, T. Tamura, 2006, Lung Cancer.

4001 ORAL Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients With Locally Advanced Non-small Cell Lung Cancer – a Phase III Trial of the Japan Clinical Oncology Group (JCOG0301)

N. Saijo, Y. Ohe, N. Yamamoto, 2011 .

Meta‐analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy‐induced anemia and mortality: Individual patient data from Japanese randomized, placebo‐controlled trials

H. Ohmatsu, N. Saijo, Y. Ohashi, 2013, Cancer science.

Chemotherapy-induced anemia in patients with primary lung cancer.

K. Eguchi, N. Saijo, Y. Ohe, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

An integrated analysis of comprehensive geriatric assessment (CGA) in elderly patients with non-small cell lung cancer (NSCLC) (JCOG1115-A).

H. Katayama, N. Saijo, Y. Ichinose, 2012 .

Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): An intergroup trial of JCOG0803/WJOG4307L.

N. Saijo, Y. Ichinose, Y. Ohe, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Multidisciplinary treatment for small cell lung cancer].

K. Eguchi, K. Tominaga, N. Saijo, 1984, Gan to kagaku ryoho. Cancer & chemotherapy.

Effect of peplomycin plus carbazilquinone and mitomycin on non-small cell carcinoma of the lung.

M. Shibuya, K. Eguchi, K. Tominaga, 1983, Cancer treatment reports.

[Evidence based chemotherapy for lung cancer].

N. Saijo, H. Watanabe, 2000, Gan to kagaku ryoho. Cancer & chemotherapy.

The frequency and management of infectious episodes and sepsis in small cell lung cancer patients receiving intensive chemotherapy with granulocyte-colony stimulating factor.

K. Eguchi, N. Saijo, Y. Ohe, 1991, Japanese journal of clinical oncology.

In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib.

Kazuko Sakai, N. Saijo, H. Yokote, 2006, The Biochemical journal.

Recent trends in the treatment of advanced lung cancer

N. Saijo, 2006, Cancer science.

Phase II study of carboplatin in small cell lung cancer.

K. Eguchi, N. Saijo, Y. Fujiwara, 1988, Japanese journal of clinical oncology.

Reasons for response differences seen in the V15-32, INTEREST and IPASS trials

N. Saijo, M. Takeuchi, H. Kunitoh, 2009, Nature Reviews Clinical Oncology.

Differences of host immune response and of sensitivity to chemotherapeutic agents between two clones of rat fibrosarcoma with different metastatic potential.

N. Saijo, A. Hamburger, H. Futami, 1986, Japanese journal of cancer research : Gann.

Effect of chemotherapy on natural-killer activity and antibody-dependent cell-mediated cytotoxicity in carcinoma of the lung.

M. Shibuya, K. Eguchi, K. Tominaga, 1982, British Journal of Cancer.

Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer.

H. Ohmatsu, N. Saijo, Y. Nishiwaki, 2007, Lung cancer.

Establishment and characterization of cisplatin‐resistant sublines of human lung cancer cell lines

N. Saijo, W. Hong, Y. Sasaki, 1988, International journal of cancer.

A Randomized Prospective Study of Imipenem‐Cilastatin With or Without Amikacin as an Empirical Antibiotic Treatment for Febrile Neutropenic Patients

K. Eguchi, N. Saijo, Y. Ohe, 1994, American Journal of Clinical Oncology.

Collateral sensitivity of cisplatin-resistant human lung cancer cell lines to thymidylate synthase inhibitors

N. Saijo, Y. Ohe, Y. Sugimoto, 1990 .

Pharmacokinetics of cisplatin and combination chemotherapy of cisplatin plus 5-FU.

N. Saijo, 1998, Japanese journal of clinical oncology.

Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines.

N. Saijo, Y. Fujiwara, K. Nishio, 1993, Cancer research.

Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials.

J. Crowley, N. Saijo, Y. Nishiwaki, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907.

N. Saijo, Y. Ichinose, Y. Nishiwaki, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor response to chemotherapy: The validity and reproducibility of RECIST guidelines in NSCLC patients 1

K. Sugimura, N. Saijo, Y. Ohe, 2003, Cancer Science.

A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients.

H. Ohmatsu, R. Kakinuma, N. Saijo, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

O-72 A pilot study of cisplatin and etoposide plus concurrent accelerated hyperfractionated thoracic radiotherapy (TRT) followed by three cycles of irinotecan and cisplatin for the treatment of limited-stage small-cell lung cancer (SCLC): JCOG 9903-DI

K. Mori, N. Saijo, Y. Nishiwaki, 2003 .

A new 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay for testing macrophage cytotoxicity to L1210 and its drug-resistant cell lines in vitro

N. Saijo, Y. Ohe, K. Miura, 2005, Cancer Immunology, Immunotherapy.

ZD0473 pharmacokinetics in Japanese patients: a Phase I dose-escalation study.

N. Saijo, H. Murakami, N. Yamamoto, 2002, European journal of cancer.

The use of human tumor clonogenic assay in predicting combination effect of cisplatin plus vindesine in carcinoma of the lung.

N. Miyazawa, N. Saijo, E. Shimizu, 1985, Journal of pharmacobio-dynamics.

Phase II study of vindesine in patients with non-small cell lung cancer.

K. Eguchi, K. Tominaga, N. Saijo, 1985, Japanese journal of cancer research : Gann.

cDNA cloning of a short type of multidrug resistance protein homologue, SMRP, from a human lung cancer cell line.

N. Saijo, K. Nishio, H. Kurokawa, 1997, Biochemical and biophysical research communications.

In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance

N. Saijo, K. Nishio, H. Arioka, 2005, Journal of Cancer Research and Clinical Oncology.

Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis.

N. Saijo, H. Kunitoh, A. Inoue, 2001, International journal of radiation oncology, biology, physics.

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.

J. Pignon, N. Saijo, M. Fukuoka, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II of ACNU for non-small cell lung cancer.

K. Eguchi, K. Tominaga, N. Saijo, 1985, European journal of cancer & clinical oncology.

Preliminary phase II study of adriamycin (ADM) in patients with non-small cell lung cancer (NSCLC).

K. Eguchi, K. Tominaga, N. Saijo, 1985, Japanese Journal of Clinical Oncology.

O-269 A phase II trial of pre-operative chemoradiotherapy followed by surgery in Pancoast tumors: initial report of Japan Clinical Oncology Group trial (JCOG 9806)

H. Kato, M. Tsuboi, N. Saijo, 2003 .

Randomized study of vinorelbine (VRB) or vindesine (VDS) with cisplatin (P) and mitomycin (M) as induction chemotherapy in stage IIIB or IV non-small cell lung cancer (NSCLC) — Final results

N. Saijo, Y. Nishiwaki, Y. Ohashi, 2000 .

Dose intensive chemotherapy for limited-stage (LS) small cell lung cancer (SCLC): A phase II study

H. Ohmatsu, N. Saijo, Y. Nishiwaki, 2005 .

Results of recent Japanese clinical trials in lung cancer.

N. Saijo, Y. Ohe, 2002, Clinical lung cancer.

Preliminary Phase II Study of 1-(2-Chloroethyl)-3-(MethylAlpha-D-Glucopyranos-6-Yl)-1-Nitrosourea (MCNU) Against Primary Lung Cancer and Metastatic Pulmonary Tumors

M. Shibuya, K. Eguchi, K. Tominaga, 1982 .

Concurrent cisplatin/etoposide (PE) and twice-daily thoracic radiotherapy (BID TRT) followed by weekly dose intensive regimen (CODE) with human granulocyte-colony stimulating factor (G-CSF) for limited stage (LS) small cell lung cancer (SCLC)

N. Saijo, Y. Nishiwaki, Y. Ohe, 2000 .

Effect of a chimeric anti‐ganglioside GM2 antibody on ganglioside GM2‐expressing human solid tumors In vivo

N. Saijo, Y. Ohe, K. Fukuoka, 1999, International journal of cancer.

Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519

N. Saijo, K. Nishio, Takashi Nakamura, 2001, Japanese journal of cancer research : Gann.

Ouabain‐resistant non‐small‐cell lung‐cancer CELL LINE SHOWS COLLATERAL SENSITIVITY TO cis‐diamminedichloroplatinum(II) (CDDP)

N. Saijo, K. Nishio, M. Adachi, 1994, International journal of cancer.

Establishment and characterization of cisplatin‐resistant sublines of human lung cancer cell lines

N. Saijo, W. Hong, Y. Sasaki, 1988, International journal of cancer.

Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells.

J. Usuda, N. Saijo, K. Nishio, 1999, International journal of oncology.

Small-cell lung cancer: current therapy and novel agents.

N. Saijo, A. Horiike, 2005, Oncology.

Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population.

Teruhiko Yoshida, N. Saijo, Y. Ohe, 2007, Drug metabolism and pharmacokinetics.

Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2).

Teruhiko Yoshida, N. Saijo, A. Ohtsu, 2003, Drug metabolism and pharmacokinetics.

Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer

A. Gemma, N. Saijo, Y. Nishiwaki, 2008, Cancer.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

J. Austin, I. Petersen, V. Rusch, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Problems involved in the clinical trials for non-small cell lung carcinoma.

N. Saijo, 2012, Cancer treatment reviews.

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, A. Nicholson, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

M. Kudo, N. Saijo, K. Nishio, 2011, Molecular Cancer Therapeutics.

9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

R. Herbst, N. Saijo, W. Eberhardt, 2009 .

Evaluation of the effects of chemotherapy in lung cancer by thoracic computed tomography

K. Mori, K. Eguchi, N. Moriyama, 1988, Cancer.

Augmentation of colony formation of cultured cell lines by pleural effusion from patients with lung cancer.

N. Saijo, W. Hong, Y. Sasaki, 1988, European journal of cancer & clinical oncology.

Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer.

H. Choy, H. Wakelee, N. Saijo, 2008, Clinical lung cancer.

A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer.

K. Eguchi, N. Saijo, Y. Ohe, 1994, European journal of cancer.

A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509.

N. Saijo, Y. Ichinose, Y. Ohe, 2012 .

Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.

N. Saijo, Y. Ichinose, Y. Nishiwaki, 2010, Japanese journal of clinical oncology.

Induction of cytochrome P450 (CYP3A4) by gefitinib in non-small cell lung cancer (NSCLC) patients

N. Saijo, Y. Ohe, N. Yamamoto, 2005 .